OncoMatch/Clinical Trials/NCT06553339
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
Is NCT06553339 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Oral HS-10516 for von hippel lindau-deficient clear cell renal cell carcinoma.
Treatment: Oral HS-10516 — The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in patients with VHL Syndrome Associated Tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: hypoxia-induced factor inhibitor
Hypoxia-induced factor inhibitors
Cannot have received: traditional Chinese medicine indicated for tumors
Exception: within 2 weeks prior to the first dose of study treatment
Traditional Chinese medicine indicated for tumors within 2 weeks prior to the first dose of study treatment.
Cannot have received: cytotoxic chemotherapy
Exception: within 3 weeks before the first dose of study treatment
Cytotoxic chemotherapeutic drugs, investigational drugs or other systematic anti-tumor therapies within 3 weeks before the first dose of study treatment
Cannot have received: investigational drug
Exception: within 3 weeks before the first dose of study treatment
Cytotoxic chemotherapeutic drugs, investigational drugs or other systematic anti-tumor therapies within 3 weeks before the first dose of study treatment
Cannot have received: systematic anti-tumor therapy
Exception: within 3 weeks before the first dose of study treatment
Cytotoxic chemotherapeutic drugs, investigational drugs or other systematic anti-tumor therapies within 3 weeks before the first dose of study treatment
Cannot have received: colony-stimulating factor
Exception: within 4 weeks before the first dose of study treatment
Colony-stimulating factors (CSFs) within 4 weeks before the first dose of study treatment
Cannot have received: local radiotherapy
Exception: within 2 weeks prior to the first dose of study treatment
Local radiotherapy within 2 weeks prior to the first dose of study treatment
Cannot have received: bone marrow radiotherapy or large-area irradiation
Exception: more than 30% of bone marrow radiotherapy or large-area irradiation within 4 weeks before the first dose of study treatment
more than 30% of bone marrow radiotherapy or large-area irradiation within 4 weeks before the first dose of study treatment
Cannot have received: major surgery
Exception: within 4 weeks prior to the first dose of study treatment
Major surgery within 4 weeks prior to the first dose of study treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify